Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label adalimumab maintenance study in Crohn's disease after M14-115
NL-OMON44259Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in Crohn's disease, sponsored by AbbVie Inc. Primary endpoint: Endoscopic improvement at Week 40 among subjects with endoscopic improvement at Week 0. Started May 2015; status: active, not recruiting.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON44259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44259.